Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor). Marbach D, Brouer-Visser J, Brennan L, Wilson S, et al. BMC Cancer 2025;25:500.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Marbach D, Brouer-Visser J, Brennan L, Wilson S, et al. Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor). BMC Cancer 2025;25:500.
PMID: 40102759